Suven Life Sciences at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Suven Life Sciences takes part in 2 sessions at CTAD 2026 in Boston. Its program centres on its serotonin 5-HT6 receptor antagonists, with baseline data from the phase 3 trial of masupirdine and a first-in-human study of a second compound.

Organization	CTAD 2026 Attendance
Suven Life Sciences Hyderabad, India
suven.com Biotech Indian drug developer running a phase 3 trial of masupirdine, a 5-HT6 antagonist, for agitation in Alzheimer's dementia.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Masupirdine (a pure 5-HT6 receptor antagonist): Baseline demographic and clinical characteristics of the phase-3 clinical study targeting agitation in patients with dementia of Alzheimer’s type (P033) Neuropsychiatric symptoms Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue First-in-Human Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a Pure M1 Positive Allosteric Modulator, in Healthy Human Subjects (P066) Other mechanisms and targets

Organization

CTAD 2026 Attendance

Suven Life Sciences

Hyderabad, India

suven.com

Biotech

Indian drug developer running a phase 3 trial of masupirdine, a 5-HT6 antagonist, for agitation in Alzheimer's dementia.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Masupirdine (a pure 5-HT6 receptor antagonist): Baseline demographic and clinical characteristics of the phase-3 clinical study targeting agitation in patients with dementia of Alzheimer’s type (P033)

Neuropsychiatric symptoms

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

First-in-Human Evaluation of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SUVN-I6107, a Pure M1 Positive Allosteric Modulator, in Healthy Human Subjects (P066)

Other mechanisms and targets

Instantly find 20 buyers from Suven Life Sciences

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction